Roger Perlmutter believes the next generation of therapies will likely come from China, not due to inherently superior innovation (yet), but because of its overwhelming investment in science and engineering. He notes that China graduates more STEM students annually than the rest of the world combined, while the US is defunding science.

In the AI arms race, placing excessive constraints on domestic AI development while adversaries like China operate without them is a form of unilateral disarmament. This could leave the entire nation's digital infrastructure, from consumer data to government secrets, vulnerable to attack by more advanced, unrestricted foreign AIs.

The most significant long-term risk to US biotech isn't foreign competition but the degradation of its basic research environment. This system attracts top global talent, and its decline will have ramifications for decades.

The market is currently ignoring the long-term impact of deep cuts to research funding at agencies like the NIH. While effects aren't immediate, this erosion of foundational academic science—the "proving ground" for new discoveries—poses a significant downstream risk to the entire biotech and pharma innovation pipeline.

Unlike the NIH's science-driven approach, the Department of Defense's new biotech funding priorities will be reactive to geopolitical threats. The DOD will invest in areas where China is perceived to be advancing, such as synthetic biology and biologic data security, rather than funding basic research.

While China is a rising competitor, the real danger to America's biotech leadership is the weakening of its own foundational pillars. Eroding NIH funding, restrictive immigration for top talent, and inefficient regulatory processes pose a greater risk than any single foreign nation.

The greatest threat to US innovation is not simply cutting NIH funding, but imposing political litmus tests on which research gets funded. This mirrors the disastrous Lysenkoism of the Soviet Union, where political ideology replaced the scientific method, guaranteeing the destruction of true innovation.

The White House is redirecting billions in research funds away from universities, which it argues have become too slow and bureaucratic. The new strategy favors direct funding to individual scientists and stronger industry partnerships, acknowledging that frontier innovation now often originates within tech companies, not traditional academia.

The disruption to the U.S. biomedical research ecosystem is not necessarily a targeted reform of science itself. Instead, it's viewed by many as 'collateral damage' in a larger political culture war against universities and perceived 'woke leftist ideologies,' with NIH funding being used as leverage.